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Abstract 
Pancreatic cancer (pancreatic ductal adenocarcinoma, PDA) is infamously moving to the top of the 
list as one of the most lethal cancers with an overall 5 year survival rate of 7%. Multiple ge-
nomic-based and molecular characterization studies of PDA specimens and established animal 
models have provided the field with multiple targets and a progression model of this disease. Still, 
to date, the best therapeutic options are surgery and combination cytotoxic therapies. In general, 
even in the best case scenario (i.e., an early stage diagnosis and a response to a specific therapy), 
most of these fortunate patients’ PDA cells acquire or exert resistance mechanisms and eventually 
kill the patient. Herein, we touch on a growing field of investigation that focuses on PDA cell 
therapeutic resistance mechanisms. We examine extrinsic elements (i.e., the tumor microenvi-
ronment, hypoxia) to the intrinsic processes within the cell (i.e., post-transcriptional gene regu-
lation and somatic mutations) that are important for therapeutic efficacy and resistance. Even as 
better targeted and personalized approaches move through the clinical trial pipeline the discussed 
resistance mechanisms will most likely play a role in the management of this deadly disease. 
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Overview of Pancreatic Cancer 
Pancreatic ductal adenocarcinoma (PDA) is a 
highly lethal malignancy with a 5-year survival rate of 
7%[1]. It is expected that by 2020 PDA will surpass 
breast and colorectal cancer to become the second 
most common cause of cancer-related deaths[2]. Cur-
rently, there are no active screening methods to detect 
PDA at early stages, and patients with localized dis-
ease exhibit no overt symptoms. Thus, PDA is often 
diagnosed too late and the few available therapeutic 
options have little durable activity. In fact, if evidence 
of the disease is detected early, the only potentially 
curative option for pancreatic cancer is surgery, fol-
lowed by adjuvant chemotherapy. Nevertheless, early 
recurrence and disease progression after surgery is 
evident in a large proportion of patients. Though the 
underlying cause(s) of recurrence or disease progres-
sion remain largely unknown, key culprits are unde-
tected micrometastases and cellular drug resistance 
mechanisms. 
 In the metastatic setting, two recent random-
ized-controlled trials demonstrated the advantage of 
combination therapies over single agent gemcitabine, 
a nucleoside analogue that had been the standard of 
care since 1997[3]. To this extent, combining Folinic 
acid, 5-Fluorouracil (5-FU), Irinotecan, and Oxali-
platin (FOLFIRINOX) provided patients with a 4.3 
month increase in overall survival when compared to 
gemcitabine alone (hazard ratio for death, 0.57; 95% 
confidence interval [CI], 0.45 to 0.73; P<0.001)[4, 5]. 
Similarly, gemcitabine plus nab-paclitaxel (abraxane) 
increased overall survival by approximately 2 months 
when compared to single-agent gemcitabine (hazard 
ratio for death, 0.72; 95% confidence interval [CI], 0.62 
to 0.83; P<0.001)[6]. Despite the recent success of these 









tably recur and succumb to their disease. In this per-
spective, we survey current therapeutic resistance 
mechanisms both extrinsically including the tumor 
microenvironment and also intrinsically within the 
cellular machinery of PDA cells (Fig. 1).  
Prelude 
We refer the reader to other outstanding reviews 
and publications on elements of the tumor microen-
vironment, drug availability and honing issues[7-10]. 
We will focus on the classical view of therapeutic re-
sistance mechanisms that are most likely intact in the 
majority of PDAs. In brief, we are aware that there are 
distinct differences between innate/acute and ac-
quired resistance therapeutic mechanisms. The so-
matic mutation section is clearly describing a putative 
acquired resistance event that would take at least 
months to develop, compared to other described 
mechanisms herein that may take only hours to dis-
rupt the biology enough to affect drug efficacy. 
However, we disclose upfront that for the purpose of 
this review we do not label each aspect of resistance as 
acute or acquired.  
1. An element of the microenvironment: Hypox-
ia-Induced Resistance: Tumor formation and the tumor 
microenvironment pose a unique set of challenges to 
the neoplastic cell including decreased glucose con-
centrations, oxidative stress, poor vascularization, low 
partial pressures of oxygen and low intratumoral 
perfusion (Fig. 1). This nutrient and oxygen poor en-
vironment imparts a selective pressure, favoring the 
growth of the most aggressive and fit PDA 
cells[11-13]. It is these cells which tend to be the most 
elusive to cytotoxic chemotherapeutic agents[11, 14, 
15]. In order to overcome the harsh stress imposed by 
chronic hypoxia (e.g.: low oxygen pressure [pO2] and 
intratumoral perfusion) PDA cells orchestrate a mul-
ti-faceted response by activating hypoxia-inducible 
factors (HIFs; e.g.: HIF-1α, PIM1, CAIX, PDK1, 
CCND1)[16]. This potent acute cellular reprogram-
ming activates pathways responsible for regulating 
cell motility, intracellular pH, mitochondrial function, 
angiogenesis, cellular metabolism, DNA repair, and 
cell survival[17-19].  
Our mechanistic understanding of hypox-
ia-induced chemoresistance is limited, particularly in 
PDA models. Many previous studies focused on the 
role of HIF-1α and its downstream effectors in this 
process. In various tumor models, HIF-1α is impli-
cated in the upregulation of VEGF, MDR/P-gp, CAIX, 
Glut1, WSB-1, Shh, LDH-A and Bcl2[20-25]. This 
transcriptional response is pleiotropic in nature and 
involved in apoptosis, cellular senescence, cellular 
metabolism, DNA repair, drug resistance, and oxida-
tive stress[20-25]. HIF-1α has been directly linked to 
PDA hypoxic chemoresistance as well. In 2014, Cheng 
et.al. demonstrated under hypoxic conditions that 
siRNA inhibition of either HIF-1α or NFκB sensitized 
PDA cells to gemcitabine and increased apoptosis[26]. 
HIF-1α downstream targets have also been implicated 
in hypoxic chemoresistance. Maftouh et.al. examined 
the role of LDH-A, an enzyme involved in anaerobic 
glycolysis and known target of HIF-1α, in hypoxic 
chemoresistance[25]. They demonstrated increased 
gemcitabine chemosensitivity utilizing both siRNA as 
well as novel LDH-A inhibitors. This study provides 
rationale for targeting cellular metabolism in con-




Figure 1: PDA resistance mechanisms. Both extrinsic factors (which include the role of surgery, tumor microenvironment, stroma, etc.) and intrinsic cellular factors 
(ranging from somatic mutations, transcriptional and post-transcriptional reprogramming) contribute significantly to acute and acquired resistance to the existing 
therapeutic approaches used for treating PDA. 





HIF-1α independent pathways have also been 
implicated in hypoxic chemoresistance in PDA. Chen 
et.al. examined PIM1, a serine/threonine kinase with 
pleiotropic effects on cell survival, apoptosis, and 
metabolism[27]. They used a dominant negative PIM1 
to rescue sensitivity to 5-FU, gemcitabine and cispla-
tin in hypoxia. They were further able to show that 
PIM1 acted to stabilize the mitochondrial membrane 
and inhibit apoptosis in a HIF-1α-independent man-
ner. Our lab has delineated the mechanism by which 
PIM1 is upregulated in hypoxia and implicated the 
RNA binding protein HuR in hypoxic chemo-
resistance (Blanco et al, Oncogene in press). This work 
demonstrates upon hypoxic stimuli, HuR (ELAVL1) is 
translocated to the cytoplasm where it stabilizes the 3’ 
UTR of the PIM1 transcript. Using siRNA as well as a 
novel pharmacologic inhibitor of HuR, the PIM1-HuR 
axis was demonstrated to be necessary for hypoxic 
chemoresistance to 5-FU and oxaliplatin. Finally, 
multiple studies by Onishi et.al have elucidated the 
importance of the sonic hedgehog (Shh) pathway in 
hypoxic chemoresistance[22, 23]. The Shh pathway is 
involved in pancreatic development and is upregu-
lated under hypoxic conditions[23, 28]. Utilizing cy-
clopamine, an Shh pathway inhibitor, the investiga-
tors rescued 5-FU and gemcitabine resistance in hy-
poxic conditions. Accordingly, using siRNA towards 
HIF-1α, they showed that Shh mediated hypoxic 
chemoresistance was HIF-1α independent.  
Translational researchers have recently at-
tempted to use the hypoxic tumor environment as a 
therapeutic advantage. TH-302 (evofosfamide) is a 
2-nitroimidazole prodrug of the cytotoxin bro-
mo-isophosphoramide mustard. Under hypoxic con-
ditions, the prodrug undergoes reduction and pref-
erentially releases the active drug in the hypoxic tu-
mor environment[29]. A recent phase II study re-
ported that co-administering TH-302 with gemcita-
bine resulted in an increase in progression-free sur-
vival in patients with advanced PDA[30]. While cur-
rent studies are being done in the backbone of gem-
citabine-abraxane, these results indicate that targeting 
tumor hypoxia may be a viable approach to overcome 
resistance in PDA. 
Although the studies outlined above have begun 
to elucidate the specific mechanisms as well as future 
avenues for targeting hypoxic chemoresistance, there 
is still much work to be done. Most studies have been 
performed using disparate model systems and cancer 
types. It is unknown how many of these mechanisms 
are tumor cell type specific or whether they represent 
more universal mechanisms of hypoxic chemo-
resistance. Furthermore, there has been no compre-
hensive evaluation using novel techniques to delve 
into this important mechanism of resistance. With the 
advent of gene editing, next generation sequencing, 
and proteomic advances over the past few years, un-
biased screens may serve to answer these questions in 
the future.  
2. Cancer Somatic mutations as drivers of resistance: 
Classical progression of pancreatic carcinogenesis has 
been classified into early (telomere shortening and 
activating mutations in KRAS), intermediate (inacti-
vating mutations or epigenetic silencing of 
CDKN2A2) and late (inactivating mutations of TP53 
and SMAD4) events[31]. High throughput sequencing 
and copy number studies of several PDA genomes 
have identified and validated genes such as KRAS, 
TP53, CDKN2A, SMAD4, etc. as well as identifying 
novel gene mutations that may be involved in cell 
growth, DNA repair, invasiveness and 
angiogenesis[15, 32-34] (Fig. 1). However, this exten-
sive understanding of the somatic genetic landscape 
of PDA has yet to substantially contribute to an im-
provement in prognosis and treatment strategies. The 
unmet need can be potentially bridged by shifting 
focus to downstream events including, metabolic re-
programming, angiogenesis alterations, cell cycle 
abnormalities, overcoming stromal-microenviron-
ment reaction, immune pathways and inflammation. 
While FOLFIRINOX and gemcitabine plus abraxane 
form the backbone of current frontline therapies for 
PDA, targeted therapeutics based on the above se-
quencing studies are being widely explored to combat 
and overcome acquired resistance in metastatic dis-
ease.  
A review of recent modern chemotherapy trials 
reveal that front-line therapy may cause a RECIST 
response (or 30% shrinkage) in 1/3 of patients[4, 14] 
and stabilize disease in another 1/3, virtually all pa-
tients will ultimately progress, with a median time to 
progression of roughly 5 months. It is fascinating to 
consider that the mechanism of PDA drug resistance 
to chemotherapy is essentially unknown. Our group 
has focused on an understudied aspect molecular 
adaptation that occurs within hours of chemotherapy 
exposure, and is governed by regulatory proteins that 
rapidly change the expression of numerous 
pro-survival proteins by affecting their RNA stability 
(see section below)[35]. However, it is tempting to 
speculate that pro-survival somatic mutations are 
acquired in response to the intense selection pressure 
imposed by chemotherapy, and these heritable mo-
lecular events predominate in resistance clones. This 
molecular pattern has been well documented in nu-
merous cancer genes, as ‘secondary mutations’ that 
occur in response to targeted therapies (e.g., KIT and 
imatinib [36], gefitinib and EGFR [37], crizotinib and 
ALK [38], vemurafanib and BRAF [39], vismodegib 
and SMO [40]). Interestingly, this theory has never 





been thoroughly investigated in pancreatic cancers 
that are resistant to standard chemotherapies. A clin-
ical trial funded by the Pancreatic Cancer Action 
Network (PI Brody) will, in part, directly address this 
question if ex vivo modeling allows for sampling of 
pre- and post- treated specimens (Fig. 2). 
3. An alternative pathway to resistance: 
Post-transcriptional gene regulation (PTGR) is the 
modulation of RNA stability and expression, primar-
ily mediated by RNA binding proteins (RBPs) and 
microRNAs (Fig. 1). Downstream effects of such 
modulation include alternative splicing, RNA pro-
cessing and nuclear export and redirecting the RNA 
towards storage, translation or degradation. For in-
stance, MUC4, a protein that plays a major role in 
pancreatic tumorigenesis, undergoes post-transcrip-
tional regulation and alternative splicing to generate a 
variant MUC4/4, which has been linked to increased 
malignancy and resistance to apoptosis[41].  
RNA-Binding proteins in cancer prognosis or 
treatment responses  
Because of their ability to globally affect varied 
regulatory networks, RBPs regulate several cellular 
processes such as cancer initiation and progression, 
immunological responses, and neurological processes. 
Specifically in the context of tumorigenesis, 
post-transcriptional modulation contributes to 
changes in tumor cell growth and proliferation, an-
giogenesis, invasion and metastasis, drug responses 
and ultimately cancer prognosis. Of particular im-
portance, RBPs such Human Antigen R (HuR), 
Tristetraproline (TTP), Sam68, eIF4E, La, AUF1, play a 
significant role in regulating tumor responses.  
HuR and chemotherapeutic resistance 
HuR’s function is largely dependent on its over-
all expression and cellular localization in response to 
cancer-associated stimuli. Stress-induced cytoplasmic 
translocation of HuR and its subsequent stabilization 
of specific pro-survival transcripts have been linked to 
drug resistance in solid tumors. For instance, 
HuR-mediated up-regulation of proteins in the 
MAPK and JNK signaling pathways has been shown 
to cause tamoxifen resistance in breast cancer MCF-7 
cells[42]. Several reports indicate the interplay be-
tween HuR and microRNA’s resulting in chemo-
therapeutic resistance in ovarian[43], prostate[44], 
breast[45], colon[46, 47] and pancreatic cancer[48, 49]. 
A recent study indicated that cancer- associated 
stressors such as a highly oxidative environment, 
starvation and DNA-damaging agents correlate with 
a selective increase in expression of HuR, which in 
turn affects the phosphorylation of the initiation fac-
tor eIF4E and results in chemotherapeutic 
resistance[50]. In PDA, HuR expression regulates the 
stability and expression of enzyme dCK, which me-
tabolizes the prodrug gemcitabine, thereby modulat-
ing response to the standard of care[51]. Another 
study pioneered the role of HuR in supporting a drug 
resistance phenotype through its stabilization of the 
mitotic kinase inhibitor, WEE1. In response to DNA 
damaging agents such as mitomycin C and platinum 
agents, HuR translocates to the cytoplasm wherein it 
stabilizes WEE1 mRNA, hence allowing cancer cells to 
pause at G2/M checkpoint, repair damaged DNA and 
evade apoptosis[35]. 
Role of MicroRNAs in cancer prognosis or 
treatment responses 
MicroRNAs (mIRs) which can rapidly and effec-
tively alter gene expression likely play a role in 
treatment efficacy[52-54]. For example, it has been 
reported that miR-22 regulates sensitivity of colorectal 
cancer cells to 5-FU by post-transcriptionally regulat-
ing crucial target genes which, in turn, facilitate au-
tophagy[55]. Several studies have also indicated a link 
between deregulated miRNA expression profiles and 
chemoresistance in Ewing’s sarcoma[56-59]. Similarly, 
microRNA signatures also influence resistance to 
TRAIL[60] and kinase inhibitors [61] in non-small cell 
lung and pancreatic cancer. 
 
 
Figure 2: PDA progression and treatment strategies. In the era of next generation sequencing and novel molecular diagnostics, the ability to use circulating tumor 
cells/DNA (and conventional biopsies) allows us to detect and map accumulated somatic mutations and molecular alterations which may be a result of disease 
progression or exposure to chemotherapy. (Abbreviations. MP- Molecular Profiling) 
 





PARP Inhibition in PDA 
Recently, Poly-ADP ribose polymerase (PARP) 
inhibitors (PARPi), which target the DNA damage 
repair (DDR) pathway, have delivered promising 
preclinical and clinical results. Mechanistically, PARPi 
work through the concept of synthetic lethality, by 
specifically targeting the Achilles’ heel of cancer cells 
that are already carrying mutations in major DNA 
repair genes. Cells deficient in these enzymes encoded 
by tumor-suppressor genes, BRCA1 and BRCA2are 
therefore heavily dependent of PARP for DNA dam-
age repair. PARP1, an enzyme with a native function 
to repair single-stranded breaks (SSBs) by base exci-
sion repair (BER) is now solely responsible for HR- 
function to repair DSBs arising from exposure to 
chemotherapy (alkylating agents, topoisomerase in-
hibitors, etc.). Therefore, inhibition of PARP1 via 
PARPi has proven to be effective towards treating 
patients with tumors that harbor mutations in DNA 
repair-related genes[62, 63]. This concept of synthetic 
lethality is a promising therapeutic strategy, which 
brings the medical oncology community closer to a 
‘personalized’ approach towards treating a subset of 
PDA patients. 
PDA stands as the third most common cancer 
associated with BRCA mutations[64]. Approximately 
10% of PDA patients carry mutations in DNA repair 
genes such as BRCA1, BRCA2, Fanconi Anemia genes, 
PALB2, etc. which makes PARP inhibition the best 
personalized approach for treating this particular 
subset of PDA patients[65, 66]. Subsets of pancreatic 
cancer with specific somatic mutations correlate with 
in vitro chemosensitivity. A recent study found that 
the sensitivity of PARP1 inhibitor, additional to 
BRCA-deficiency, was influenced by expression pro-
files of DNA damage repair (DDR) pathway genes 
(ERCC3, RAD17, SUMO1, MUTYH, CRY1, HSP90B1, 
CDC37, RXRA, and USP5) [67]. Additionally, a screen 
identified the deubiquitylating enzyme USP11 as a 
participant in HR repair of DSBs. The loss of USP11 
caused impaired recruitment of a subset of DSB repair 
proteins such as RAD51 and 53BP1 to the repair foci 
[68]. This suggests that, apart from BRCA and FA 
genes, PARP1 demonstrates synthetic lethality with 
other DDR genes. PARP1 is known to be hyperactive 
in BRCA1- or BRCA2-deﬁcient cells and p53 also 
plays a role as a regulator of DNA repair pathways. 
PARP1 is shown to be hyperactive in BRCA1- or 
BRCA2-deﬁcient cells. TP53 also plays a role as a reg-
ulator of DNA repair pathways. Therefore, patients 
carrying a gene defect in the DSB repair pathways 
together with p53 mutations are selected for PARP 
inhibitor therapy[69]. Currently, PARP inhibitors are 
in different phases of clinical trials, either as single 
agent (Olaparib) or in combination (Olaparib, Velipa-
rib, Rucaparib, BMN673) with standard of care gem-
citabine or other chemotherapeutic agents for treating 
patients with locally advanced, unresectable or meta-
static pancreatic cancer.  
However, de novo and acquired resistance to 
PARP inhibitors poses a signiﬁcant clinical problem 
[70, 71]. To date, four PARPi resistant mechanisms 
have been highlighted in the literature [72]. A) Tar-
geted mutation reversion: Successful targeted thera-
pies in cancer can induce reversion mutations in a cell 
with a hypermutable state (e.g., Gleevec giving rise to 
BCR-Abl mutations) [73]. Secondary, reversion muta-
tions that restore deleterious BRCA2 mutant function 
have been the predominantly described mechanism 
for PARP inhibitor resistance[74], and have been 
shown to be a result of acquired, not de novo mecha-
nisms[75]. These findings were reproduced in cancer 
cells exposed to platinum-based therapies [76, 77]. A 
thorough study of independently derived PARPi- 
resistant BRCA2- mutant CAPAN1 cell lines indicated 
that BRCA2 function is not typically restored upon 
prolonged exposure to PARPi. Instead, deletion 
events in BRCA2 DNA either restored the ORF that 
encodes the C-terminal RAD51 binding domain or 
resulted in small tracts of DNA sequence homology 
arising from error-prone repair due to BRCA2 defi-
ciency [77]. Perhaps the best evidence of a targeted 
mutation reversion came from a PARPi (olaparib) 
study that performed DNA sequencing on treat-
ment-naive and post- treatment biopsies. However, 
only two patients harbored BRCA2 reversion muta-
tions in olaparib-resistant metastases that restored 
BRCA2 function [78]. B) Hypermorphic/unclassified 
BRCA-alleles: Not all identified mutated BRCA1/2 
patients respond to PARPi therapy and thus under-
standing all disease-related BRCA-alleles will be crit-
ical in predicting which patients will respond best to 
PARPi-based therapy. C) Ineffective PARPi uptake or 
drug export: Early pharmacodynamics studies have 
demonstrated that PARPi uptake is effective [79, 80], 
yet a P-glycoprotein-mediated drug resistance 
mechanism has been demonstrated in a mouse model 
[81]. Elevated expression of ABCB1, a P-glycoprotein 
efflux pump has been shown to cause Olaparib re-
sistance; this can be abrogated by treatment with a 
PgP inhibitor, tariquidar[81]. However, it remains 
unknown whether these findings have any implica-
tions for patients. D) Rewiring of the DNA Damage 
Response: A more likely but complicated resistance 
mechanism is the compensation of DNA repair net-
work, which will result in negating the ‘synthetic le-
thal’ setting in HR-deficient pancreatic cancer cells. 
Compensatory loss of another DNA repair factor, 
p53-binding protein 1 (53BP1) reduces 





non-homologous end joining (NHEJ) efficiency and is 
one of the best described DDR rewiring causing 
PARPi resistance [82, 83]. However, neither the vali-
dation of this DDR rewiring, nor the involvement of 
these molecules as biomarkers, have been fully estab-
lished in human tumor samples from clinical trials.  
An alternative post-transcriptional PARPi re-
sistance mechanism (revisiting HuR): Recently, our 
group showed evidence that strongly suggests that 
PDA cells develop resistance to DNA damaging 
agents through post-transcriptional gene 
regulation[84] through the RNA-binding protein, 
HuR. Primarily localized in the nucleus, HuR trans-
locates to the cytoplasm in response to cellular stress 
(e.g., DNA damage, nutrient depletion, and hypox-
ia)[85], where it becomes functionally active as a stress 
response protein. As an RBP, HuR binds to the 
AU-rich elements (AREs) typically in the 
3’-untranslated regions (UTRs) of specific, survival 
target genes involved in cell proliferation, evading 
apoptosis [86], and mitotic inhibition (e.g., the mitotic 
kinase inhibitor WEE1) [84, 87-90]. Importantly, we 
have shown that chemical and genetic silencing of 
HuR results in modulation of key cell cycle regulator, 
WEE1 and efficacy of chemotherapy [84]. Indeed, a 
seminal study demonstrated that WEE1 inhibition 
enhances accumulation of lethal DNA damage and 
apoptosis, thereby enhancing sensitivity to PARP in-
hibitors in pancreatic cancer cells[91]. We have pre-
liminary data demonstrating that PARPi: 1) induces 
HuR translocation from the nucleus to the cytoplasm 
and 2) HuR can regulate pro-survival transcripts that 
diminish the efficacy of PARPi and ultimately maybe 
a critical factor in causing PDA resistance to this tar-
geted therapy (Chand et al., unpublished). Future 
studies will determine the significance that HuR bi-
ology has on the clinical effectiveness of PARPi-based 
therapies.  
Non-cellular mechanisms affecting ther-
apeutic resistance 
The above described cellular and molecular 
mechanisms either discuss how the milieu and/or the 
molecular machinery contribute to therapeutic re-
sistance. Below we discuss how therapeutic pressures 
could either select for or strengthen metastatic clones. 
We also discuss possibilities in which to enhance 
outcomes (Fig. 3).  
Surgery. Surgical resection provides the best 
chance of long term survival. The three-year survival 
for even the most effective modern chemotherapeutic 
regimens is 5% or less [4, 14]. In contrast, the 5-year 
survival in large surgical series is close to 20%, and 
roughly 1/3 of patients survive over 3 years [92]. 
Nevertheless, it is justifiable to question the role of 
surgery for the treatment of pancreatic cancer at all. 
The recurrence rate after resection, which is a 
pre-selected group of patients with a relatively fa-
vorable prognosis, is in excess of 90% [92]. Converse-
ly, the cure rate is less than 10%. It stands to reason 
that occult residual disease (distant sites, regional 
metastases, or at the resection margin), are present in 
the majority of patients. Thus, why is resection a viable 
option, if the disease is so often systemic?  
 
 
Figure 3: Combating PDA therapeutic resistance. Patients eligible for surgical resection can be further stratified to optimize treatment, gain maximal response after 
resection and improve prognosis by exploring neoadjuvant chemotherapy, anti-growth factor therapy, etc. to keep the tumor localized and prevent micrometastases. 
In the patients with metastatic disease, local or advanced, inhibiting the intrinsic pathways through combination ‘targeted’ strategies can improve response to current 
standard- of- care therapies. (Abbreviations. NGS- Next Generation Sequencing) 





The strongest evidence in favor of surgery for 
localized disease is not biologic, but actually empiric. 
In Japan, forty-two patients with localized and resec-
table disease were randomized to resection and no 
adjuvant therapy vs. exploratory laparotomy and bi-
opsy only, followed by chemoradiation. There were 
no long-term survivors in the group of patients who 
did not undergo resection, while 20% of patients in 
the resection group lived more than 3 years. There-
fore, unlike most other cancers, the benefit of resec-
tion to treat pancreatic cancer is supported by ran-
domized data. From a biologic standpoint, resection is 
able to functionally achieve a ‘complete response’ in 
one day’s work (that is, render the patient with no 
radiographic evidence of disease). The patient typi-
cally has recovered completely by two months after 
surgery. In contrast, the most effective chemotherapy 
regimens are unable to achieve this result over the 
course of 6 months of treatment. If patients with pan-
creatic cancer ultimately die from a cancer syndrome 
when a critical volume of disease burden has been 
reached, then a complete resection can lengthen life 
by debulking 99% of the cancer cells. Assuming a 
cancer doubling time of 100 days, six doublings, or 
two years, are required to return to the pre-resection 
disease burden [93].  
Rather than render surgery obsolete, it is more 
likely that improvements in chemotherapy in the fu-
ture will expand the number of patients who are eli-
gible or will likely benefit from resection. Simplisti-
cally, as treatments to control systemic disease im-
prove, control of local disease by resection and/or 
radiation will likely become more important. Pro-
spective, single-institution studies (albeit 
non-randomized) with modern multi-agent therapy 
reveal that the majority of patients with locally ad-
vanced disease may be converted from ‘unresectable’ 
to resectable, which far exceeds historical figures [94]. 
Despite the isolated, non-randomized studies 
surfacing now, the fact remains that roughly 20% of 
patients in the general population who develop pan-
creatic adenocarcinoma will have localized and re-
sectable disease[95]. Pancreatic cancer is staged ac-
cording to the AJCC TNM, 7th Ed. and based on the 
presence of regional lymph node metastases, distant 
metastases, and cancer involvement of major visceral 
vessels[96]. However, from a practical perspective, 
pancreatic cancer is surgically staged to determine 
resectability. Cancers localized to the pancreas are 
typically staged for resection using a multislice CT 
scan using three contrast phases (early arterial, late 
arterial, and venous) to carefully examine the rela-
tionship of the tumor to nearby vessels [97]. Localized 
cancers that do not invade and distort the superior 
mesenteric vein or portal vein, and do not abut the 
superior mesenteric or celiac arteries, are considered 
resectable and patients are typically offered resection 
(although neoadjuvant chemotherapy is an acceptable 
option). When the veins are distorted, or the arteries 
abutted by the tumor, the cancer is considered ‘bor-
derline resectable,’ and most surgeons favor a neo-
adjuvant approach, using chemotherapy (with or 
without the addition or chemoradiation). Invasion of 
the veins with a technically reconstruction option, or 
encasement of the arteries indicate that the cancer is 
locally advanced, and unlikely to be treatable by re-
section. Modern chemotherapy regimens have in-
creased the percentage of patients who are able to 
undergo an attempt at resection, after a course of ne-
oadjuvant treatment for borderline or locally ad-
vanced pancreatic cancer. 
Considerations: Although surgery is probably ‘the 
best’ option for a patient diagnosed with PDA and 
better adjuvant therapies need to be developed in 
order to improve outcomes, a few considerations re-
main about resectional therapy (Fig. 1): 1) Identifica-
tion of biomarkers of early recurrence or progression, 
in order to spare patients with particularly aggressive 
cancers unnecessary surgery. 2) Examining the role of 
neoadjuvant treatment for resectable PDA. 3) Deter-
mining whether surgery, in some instances, cause a 
milieu in which growth factors or tissue dissection 
activate the spreading of micrometastateses. 4) Iden-
tifying whether neoadjuvant therapy, although rele-
vant for down staging for resection, ultimately adds a 
selection process on distant metastatic cells and 
eventually strengthens the metastatic clones. 
Immunotherapies: Tumor immunotherapy has 
become an effective tool in the treatment of many 
diseases, most notably melanoma[98]. A recent phase 
I study which evaluated the combination of an agonist 
CD40 monoclonal antibody in combination with 
gemcitabine in patients with metastatic chemothera-
py-naive PDA indicated promise, though marginal 
[99]. Although it appears that like most promising 
therapeutics, PDA appears to be unresponsive to 
several new and established immunotherapeutic 
strategies. We do acknowledge the progress made 
and pursuit for a successful vaccine for use as a ther-
apy [100].  
Considerations: The mutational and cellular het-
erogeneity of PDA makes this a difficult disease to 
bolster the immune system to fight against. Thus, 
although tumor immunotherapy is an extremely 
promising strategy to combat cancer, 1) it remains to 
be determined if it is an effective treatment option for 
PDA cells. 2) Further studies are required to define if 
there are too few tumor infiltrating B lymphocytes 
that can circulate and find their way to PDA tumor 
cells in order for a T-cell based therapeutic strategy to 





work. 3) Future investigation should identify whether 
depleting the cellular elements of the tumor microen-
vironment will allow for proper honing and targeting 
of immuno- and chemotherapy. 4) Recognizing if 
PDA cells produce factors or enzymes, such as IDO2, 
that need to be targeted in order to truly combat the 
immune blockage against PDA.[101] 
Targeted and personalized (and combination thera-
pies): Combination therapies and even cytotoxic 
therapies along with new targeted approaches are 
being evaluated in clinical trials. Even in the best 
‘personalized approach’ scenario, these targeted or 
combinatory approaches will most likely yield re-
sistant PDA cells. As the therapies become better and 
we establish a better understanding of a molecularly 
tailored approach to treating PDA patients, we may 
need to think about other aspects of combination 
therapy and personalized approaches to treating this 
disease.  
Considerations: 1) Determining the importance of 
the ‘timed sequencing’ of drug administration in 
combination treatment strategies in an effort to slow 
down and overcome resistance mechanisms. For in-
stance, if one drug induces the subcellular localization 
of HuR (see above), that induces a survival network 
for another drug, it is crucial to determine if these 
drugs should be given separately or spaced out over 
days versus hours. 2) Additional elements of the cell 
machinery (not discussed here) include the adaptable 
phosphoproteome. As technologies advance, follow-
ing the phosphoproteomic signature may be very 
relevant to drug resistance and optimal drug selection 
for a patient who recurs for 2nd and 3rd line thera-
pies(Fig. 2) [102]. 3) Evaluate if targeting a specific 
disrupted pathway could either be trumped or further 
enhanced by the addition of a cytotoxic agent (e.g., a 
generic DNA damaging agent could potentially set 
the stage for a targeted approach against a DNA re-
pair pathway such as PARP inhibition).  
Future directions  
We are hopeful that an era of better drug selec-
tions and therapeutic options are around the corner 
for PDA patients. Yet, until ‘personalized medicine’ 
and better targeted therapies are ready for the clinic, 
optimizing current therapeutic strategies that have 
activity in patients will be critical. Similarly, even if 
‘personalized therapy’ becomes a reality, we will need 
to better understand how PDA cells become resistant 
to the best matched, available therapies (Fig. 3). Mon-
itoring every patient’s tumor in real time (i.e., biop-
sying and sequencing the tumor as a moving target) is 
what we may need to do to manage this disease ef-
fectively (Fig. 2).  
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